SSRD and Overweight

The investigators have previously found that a starch- and sucrosereduced diet (SSRD) has led decreased gastrointestinal symptoms in patients with irritabel bowel syndrome (IBS). At the same time, investigators found that the weight was reduced and the nutrient intake was improved with a more favorable metabolic profile. However, it is a challenge to change lifestyle, and most persons fail to keep on with an improved diet for a long time. Investigators therefore now want to conduct a clinical trial with SSRD in overweight/obesity for 3 months. Persons with a BMI \>25 kg/m2 will be included. To examine whether a feedback about improved metabolic profile enhances the compliance, participants will be randomized to be informed or not about the metabolic profile after the 6-week visit. Investigator´s hypothesis is that information about the improvement in the metabolic profile should increase the motivation and compliance in the patients, and thereby render better effects.

NCT Number	NCT07372235
Lead Sponsor	Region Skane
Conditions	Overweight (BMI > 25)
Enrollment	300 participants
Start Date	2026-09-01
Primary Completion	2029-12-30 (estimated)
Study Completion	2032-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-29